2 completed, 2 withdrawn. 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Withdrawn 2, Completed 1 |
Follow Endourage, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use Endourage 1200 mg OMD ™ Oral Mucosal Drops, Isolate, Placebo - Alcohol Drinking, Alcohol Use, Unspecified | Not applicable | Withdrawn | Endourage, LLC | 2025-09-01 | 2025-08-07 | |
| Double-Blind Randomized Placebo-Controlled Trial of a Proprietary Full Hemp Flower Formulation for Long COVID Xltranplus, Xltran - Post-acute COVID-19 Syndrome | Not applicable | Withdrawn | LUCINDA BATEMAN, MD | 2024-08-01 | 2025-07-17 | |
| Symptom Tracking in Long COVID Patients Using Formula C™ Sublingual Drops Endourage Targeted Wellness Formula C™, a full hemp flower extract - Long COVID, Long Covid19 | Completed | Endourage, LLC | 20 | 2023-12-13 | 2025-02-25 | |
| Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome. Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C) - Covid 19 | Not applicable | Completed | Endourage, LLC | 32 | 2021-04-02 | 2025-08-07 |
Post-Acute COVID-19 Syndrome (2) · Alcohol Abstinence (1) · Alcohol Drinking (1) · Alcohol-Related Disorders (1) · COVID-19 (1)
peppermint oil (1)
United States (4)
Lucinda Bateman, MD (1) · Michael Steward, MD (1) · Thomas P Young, PhD NP (1) · Thomas P Young, PhD, NP (1)
PMID 12648025, PMID 16251991, PMID 16699809, PMID 18422832, PMID 26373473, PMID 29307505, PMID 36252151